Arcus Biosciences
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Conditions
- Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 720
- Registration Number
- NCT07011719
Drug-Drug Interaction Study of Casdatifan in Healthy Adult Participants (ARC-29)
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT06919991
- Locations
- πΊπΈ
Celerion, Tempe, Arizona, United States
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 610
- Registration Number
- NCT06608927
- Locations
- πΊπΈ
Mayo Clinic Arizona - Phoenix Campus, Phoenix, Arizona, United States
πΊπΈUniversity of Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈCancer & Blood Specialty Clinic - Los Alamitos, Los Alamitos, California, United States
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT06120075
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Denver, Colorado, United States
πΊπΈGeorgetown, Washington, District of Columbia, United States
πΊπΈEmory University, Atlanta, Georgia, United States
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AB801 in Healthy Volunteers
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06004921
- Locations
- π¬π§
Quotient Sciences - Nottingham, Nottingham, United Kingdom
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05999513
- Locations
- πΊπΈ
Celerion, Inc., Lincoln, Nebraska, United States
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
- Conditions
- Bladder CancerAdvanced MalignanciesHead and Neck Squamous Cell Carcinoma (HNSCC)Advanced CancerEsophageal CancerGastric CancerNon-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05891171
- Locations
- πΊπΈ
Mayo Clinic Arizona, Phoenix, Arizona, United States
πΊπΈMayo Clinic Florida, Jacksonville, Florida, United States
πΊπΈLake City Cancer Care, LLC., Lake City, Florida, United States
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- Conditions
- Advanced Upper Gastrointestinal Tract Adenocarcinoma
- Interventions
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 1040
- Registration Number
- NCT05568095
- Locations
- πΊπΈ
Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States
πΊπΈPrisma Health Cancer Institute, Greenville, South Carolina, United States
π¦π·CORI, La Rioja, Argentina
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20)
- Conditions
- Clear Cell Renal Cell CarcinomaSolid Tumors
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Arcus Biosciences Inc.
- Target Recruit Count
- 7
- Registration Number
- 2024-519142-70-00
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈUCLA, Santa Monica, California, United States
πΊπΈUniversity of Miami, Miami, Florida, United States
A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer
- Conditions
- Healthy Participants
- Interventions
- Drug: [14C]-etrumadenant
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05411146
- Locations
- π³π±
PRA Health Sciences (PRA) - Early Development Services (EDS), Groningen, NZ, Netherlands